Business
Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.
FEATURED STORIES
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
SciNeuro Pharmaceuticals, based in Shanghai, China, launched with a $100 million Series A financing.
The funds will be used to support the development of the company’s REMaster technology platform. In addition, Remix will now be able to advance its pipeline of RNA processing targeted therapeutics as well.
Diversity and Inclusion (D&I) have been at the forefront of the national conversation during this momentous year, so BioSpace felt it imperative to reach out to employees in the life sciences industry on this subject in our wide-ranging Fall 2020 Diversity and Inclusion Survey.
With support from Peter Thiel, Eli Lilly partner AbCellera looks to join the NASDAQ with the biggest Canadian biotech debut on record.
Experts anticipated his nomination as Biden’s Attorney General instead.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
The collaboration with Atara will focus on developing an off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day.
Has China found a super-soldier formula through the capabilities of genetic engineering? A U.S. govt. official claims, China Super Soldiers are under development.
Therapies developed using E3 ligase proteins will get a potent infusion, as AbbVie combines its commercialization expertise with Frontier Medicine’s proprietary chemoproteomics platform to develop potentially efficacious therapies for difficult-to-drug protein targets.